McNeil proposed aspirin claims "unsupported," Aspirin Foundation of America protests.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL PROPOSED ASPIRIN LABEL WARNINGS "UNSUPPORTED," AFA CLAIMS in June 10 comments to FDA. The Aspirin Foundation of America objects to McNeil's recent proposal to FDA that aspirin labeling advise physician consultation for analgesic or antipyretic use when aspirin is being taken chronically for cardiovascular benefits. "The proposal, like other elements of McNeil's marketing campaign, is wholly unsupported by science and should be categorically dismissed," AFA maintains.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning